• Drug Farm

  Participated · Series D · Jul 2026

  Drug Farm leverages proprietary platforms—IDInVivo+ (which integrates genetics and AI to identify and validate targets in living systems) and MedChem5 (used to advance first-in-class candidates)—to discover and progress drug candidates. The company is developing treatments across rare disease, cardiovascular, kidney, metabolic, autoimmune, and infectious disease indications. Its lead program, DF-003, is a first-in-class ALPK1 inhibitor that has shown clinical improvement in an ongoing Phase 1b study for ROSAH syndrome and is positioned to enter a Phase 3 trial; DF-003 has received multiple FDA designations including Fast Track and Orphan Drug. Another key program, DF-006, is an orally administered ALPK1 agonist immunomodulator that completed single and multiple ascending dose evaluations in healthy volunteers and in virologically suppressed HBeAg-negative chronic hepatitis B patients, showing encouraging anti-HBV activity. Drug Farm has entered a clinical collaboration with Xiamen Amoytop Biotech to develop DF-006 for hepatitis B and hepatocellular carcinoma. The recent $55 million Series D first closing provides capital to advance pivotal trials, global development, regulatory activities, and R&D expansion.

No current team members are available.